



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/964,956	09/26/2001	Valerie L. Gerlach	21402-124 (CURA-424) 2560			
30623	7590 04/01/2004		EXAMINER			
·	EVIN, COHN, FERRIS	MARTINELL, JAMES				
AND POPEO, P.C. ONE FINANCIAL CENTER			ART UNIT	PAPER NUMBER		
	BOSTON, MA 02111			1631		
			DATE MAILED: 04/01/2004			

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati	on No.	Applicant(s)			
	09/964,9	56	GERLACH ET AL.			
Office Action Summa	Examine	r	Art Unit			
	James M		1631			
The MAILING DATE of this cor Period for Reply	nmunication appears on th	e cover sheet with the o	correspondence address			
A SHORTENED STATUTORY PERI THE MAILING DATE OF THIS COM Extensions of time may be available under the pre- after SIX (6) MONTHS from the mailing date of the If the period for reply specified above, the maxi- Failure to reply within the set or extended period of Any reply received by the Office later than three rearned patent term adjustment. See 37 CFR 1.76	MUNICATION. Divisions of 37 CFR 1.136(a). In no eving a communication. Thirty (30) days, a reply within the starnum statutory period will apply and wor reply will, by statute, cause the appronths after the mailing date of this communication.	vent, however, may a reply be tin atutory minimum of thirty (30) day will expire SIX (6) MONTHS from plication to become ABANDONE	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C.§ 133).			
Status						
1) Responsive to communication	(s) filed on <u>12 January 200</u>	<u>94</u> .				
2a) This action is FINAL.	This action is FINAL . 2b) This action is non-final.					
3) Since this application is in con	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims		•				
4a) Of the above claim(s) 5) ☐ Claim(s) is/are allowed 6) ☑ Claim(s) <u>5,9,10,12-14,19-21,3</u> 7) ☐ Claim(s) is/are objected	Claim(s) 5,9,10,12-14,19-21,39 and 50 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 5,9,10,12-14,19-21,39 and 50 is/are rejected.					
Application Papers						
9)☐ The specification is objected to						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) in 11) The oath or declaration is obje			objected to. See 37 CFR 1.121(d). se Action or form PTO-152.			
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a a) All b) Some * c) Non 1. Certified copies of the p 2. Certified copies of the p 3. Copies of the certified copies	e of: priority documents have be priority documents have be copies of the priority docun ernational Bureau (PCT R	een received. een received in Applica ments have been recei ule 17.2(a)).	ation No ved in this National Stage			
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing R Information Disclosure Statement(s) (PTO-Paper No(s)/Mail Date 1/25/02 12/1/02	1449 or PTO/SB/08)	4) Interview Summa Paper No(s)/Mail 5) Notice of Informal 6) Other:				

Application/Control Number: 09/964,956

Art Unit: 1631

The references crossed out on form 1449 submitted January 25, 2002 are duplicate entires.

The disclosure is objected to because of the following informalities.

(a) The amendment filed January 12, 2004 is in improper form in that it recites:

"6-8. (canceled) The nucleic acid molecule of claim 5, wherein the nucleic acid
molecule comprises the nucleotide sequence of a naturally-occurring allelic
nucleic acid variant." This is unclear. However it is later (page 7) made clear
that claims 6-8 are cancelled. Applicants are required to submit a clean copy of
the claims in any response to this Office action in order for that response to be
considered to be fully responsive.

Appropriate correction is required.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 5, 9, 10, 12-14, 19-21, 39, and 50 are rejected under 35 U.S.C. 101 because the claimed invention lacks patentable utility. This rejection is repeated for reasons already of record (e.g., Office action mailed September 11, 2003. Applicants' arguments (response filed January 12, 2004, pages 8-9 are not convincing. Applicants assert that SEQ ID NO: 13 may be used as a kidney cancer cell marker. However, there is no clear connection between expression of SEQ ID NO: 13 and any disease or condition in the part of the application alluded to by applicants (*i.e.*, pages 237-255).

Claims 5, 9, 10, 12-14, 19-21, 29, and 50 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The discussion in the previous rejection is incorporated here.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1631

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Martinell whose telephone number is (571) 272-0719. The fax phone number for Examiner Martinell's desktop workstation is (571) 273-0719. The examiner works a flexible schedule and can be reached by phone and voice mail. Alternatively, a request for a return telephone call may be e-mailed to james.martinell@uspto.gov. Since e-mail communications may not be secure, it is suggested that information in such requests be limited to name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (571) 272-0722.

PLEASE NOTE THE NEW FAX NUMBER

The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

James Martinell, Ph.D. Primary Examiner

Art Unit 1631

3/30/04